Bleeding in patients with continuous-flow left ventricular assist devices: acquired von Willebrand disease or antithrombotics?
- 31 October 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 62 (1)
Abstract
OBJECTIVES: To evaluate the competing pro-haemorrhagic contribution of acquired von Willebrand (vW) disease and antithrombotic therapy in patients implanted with continuous-flow left ventricular assist devices (LVADs). METHODS: We compared the extent of vW factor (vWf) degradation [vWf antigen (vWf:Ag)] and a decrease of functional activity of large vWf multimers [vWf collagen binding (vWf:CB)] in LVAD patients who did and did not suffer from bleeding. Data were measured pre-implant, at short-term (t1: 12 months) follow-up. The occurrence of primary bleeding events, as well as bleeding recurrence, was correlated with patient-specific vWf profile and antithrombotic regimen. Indeed, patients were discharged on warfarin (international normalized ratio: 2–2.5) and aspirin, with the latter withhold after a first bleeding episode. RESULTS: Fifty-three patients were enrolled. The median follow-up was 324 (226–468) days. We recorded 25 primary bleeding events (47% of patients). All primary events occurred in patients on warfarin and aspirin. Both vWf:Ag and vWf:CB decreased significantly post-implant (P = 0.0003 and P < 0.0001), and patients showing pathological vWf:CB/vWf:Ag ratio (<0.7) increased progressively over the time of support (pre-implant = 26%, t1 = 58%, t2 = 74%; P < 0.0001). Of note, activity of large vWf multimers of bleeders was significantly lower at t2 with respect to non-bleeders (vWf:CB: 61 (36–115) vs 100 (68–121), P = 0.04; vWf:CB/vWf:Ag ratio: 0.36 (0.26–0.61) vs 0.58 (0.33–0.96), P = 0.04). Despite these marked differences in the vWf profile, following aspirin discontinuation only 3 patients had bleeding recurrence. CONCLUSIONS: Aspirin contributes significantly to haemorrhagic events in the background of acquired vW disease; its discontinuation significantly reduces bleeding recurrence. Clinical trial registration: https://clinicaltrials.gov/ct2/show/NCT03255928; ClinicalTrials.gov Identifier: NCT03255928.Keywords
This publication has 26 references indexed in Scilit:
- Platelet Secretion Defects and Acquired von Willebrand Syndrome in Patients With Ventricular Assist DevicesJournal of the American Heart Association, 2018
- Platelet Activation is a Preoperative Risk Factor for the Development of Thromboembolic Complications in Patients with Continuous-Flow Left Ventricular Assist DeviceEuropean Journal of Heart Failure, 2017
- von Willebrand factor disruption and continuous-flow circulatory devicesThe Journal of Heart and Lung Transplantation, 2017
- Outcomes in HeartMate II Patients With No Antiplatelet Therapy: 2-Year Results From the European TRACE StudyThe Annals of Thoracic Surgery, 2017
- Acquired von Willebrand syndrome associated with left ventricular assist deviceBlood, 2016
- Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand diseaseThrombosis Research, 2016
- Pathologic von Willebrand factor degradation with a left ventricular assist device occurs via two distinct mechanisms: Mechanical demolition and enzymatic cleavageThe Journal of Thoracic and Cardiovascular Surgery, 2015
- Platelet dysfunction and acquired von Willebrand syndrome in patients with left ventricular assist devices†European Journal of Cardio-Thoracic Surgery, 2014
- Diagnosis and classification of von Willebrand diseaseBlood Coagulation & Fibrinolysis, 2011
- Statistics review 8: Qualitative data – tests of associationCritical Care, 2004